Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk of a future first-ever myocardial infarction in women

References

• Sarnak MJ, Levey AS, Schoolwerth AC, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42(5):1050–1065.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293(14):1737–1745.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545–1552.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Matsushita K, Arnlov J, CKD Prognosis Consortium, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nerpin E, Ingelsson E, Riserus U, et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant. 2011;26(9):2820–2827.
   PubMed Web of Science ®Google Scholar
• Grubb A. Shrunken pore syndrome – a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clin Biochem. 2020;83:12–20.
   PubMed Web of Science ®Google Scholar
• Zhou H, Yang M, He X, et al. eGFR, cystatin C and creatinine in shrunken pore syndrome. Clin Chim Acta. 2019;498:1–5.
   PubMed Web of Science ®Google Scholar
• Grubb A. Glomerular filtration and shrunken pore syndrome in children and adults. Acta Paediatr. 2021; doi: https://doi.org/10.1111/apa.15846.
   PubMed Web of Science ®Google Scholar
• Grubb A, Lindström V, Jonsson M, et al. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. Scand J Clin Lab Invest. 2015;75(4):333–340.
   PubMed Web of Science ®Google Scholar
• Jonsson MH, Åkesson A, Hommel A, et al. Markers of renal function at admission and mortality in hip fracture patients – a single center prospective observational study. Scand J Clin Lab Invest. 2021;81(3):201–207.
   PubMed Web of Science ®Google Scholar
• Herou E, Dardashti A, Nozohoor S, et al. The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFRcystatin C/eGFRcreatinine-ratio. Scand J Clin Lab Invest. 2019;79(3):167–173.
   PubMed Web of Science ®Google Scholar
• Ljungberg J, Johansson B, Bergdahl IA, et al. Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk for future surgery for aortic stenosis. Scand J Clin Lab Invest. 2019;79(7):524–530.
   PubMed Web of Science ®Google Scholar
• Söderström E, Eliasson M, Johnson O, et al. Plasma folate, but not homocysteine, is associated with Apolipoprotein A1 levels in a non-fortified population. Lipids Health Dis. 2013;12(74):1–11.
   PubMed Web of Science ®Google Scholar
• Norberg M, Wall S, Boman K, et al. The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action. 2010;3. doi: https://doi.org/10.3402/gha.v3i0.4643
   Web of Science ®Google Scholar
• Hallmans G, Agren A, Johansson G, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort – evaluation of risk factors and their interactions. Scand J Public Health Suppl. 2003;61:18–24.
   PubMedGoogle Scholar
• Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl. 2003;61:9–17.
   PubMedGoogle Scholar
• Grubb A, Horio M, Hansson LO, et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem. 2014;60(7):974–986.
   PubMed Web of Science ®Google Scholar
• Nyman U, Grubb A, Larsson A, et al. The revised Lund-Malmo GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med. 2014;52:815–824.
   PubMed Web of Science ®Google Scholar
• Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr. 2012;22(1):120–127.
   PubMed Web of Science ®Google Scholar
• Wennberg P, Wensley F, Di Angelantonio E, et al. Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women. Thromb Res. 2012;129(1):68–73.
   PubMed Web of Science ®Google Scholar
• Van Guelpen B, Hultdin J, Johansson I, et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009;266(2):182–195.
   PubMed Web of Science ®Google Scholar
• Åkesson A, Lindström V, Nyman U, et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scand J Clin Lab Invest. 2020;80(5):412–422.
   PubMed Web of Science ®Google Scholar
• Brosnan JT, da Silva RP, Brosnan ME. The metabolic burden of creatine synthesis. Amino Acids. 2011;40(5):1325–1331.
   PubMed Web of Science ®Google Scholar
• Elshorbagy AK, Oulhaj A, Konstantinova S, et al. Plasma creatinine as a determinant of plasma total homocysteine concentrations in the Hordaland Homocysteine Study: use of statistical modeling to determine reference limits. Clin Biochem. 2007;40(16-17):1209–1218.
   PubMed Web of Science ®Google Scholar
• Christensson A, Grubb A, Molvin J, et al. The shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population – the HARVEST study. Scand J Clin Lab Invest. 2016;76(7):568–574.
   PubMed Web of Science ®Google Scholar
• Xhakollari L, Jujic A, Molvin J, et al. Proteins linked to atherosclerosis and cell proliferation are associated with the shrunken pore syndrome in heart failure patients: Shrunken pore syndrome and proteomic associations. Proteomics Clin Appl. 2021;2000089. doi: https://doi.org/10.1002/prca.202000089.
   PubMed Web of Science ®Google Scholar
• Dardashti A, Nozohoor S, Grubb A, et al. Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scand J Clin Lab Invest. 2016;76(1):74–81.
   PubMed Web of Science ®Google Scholar
• Almen MS, Björk J, Nyman U, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins. Kidney Int Rep. 2019;4(1):67–79.
   PubMed Web of Science ®Google Scholar
• Yoshii I, Nishiyama S. The impact of shrunken pore syndrome in patient with rheumatic diseases on bone mineral metabolism. Scand J Clin Lab Invest. 2021;81(1):72–81.
   PubMed Web of Science ®Google Scholar
• Astor BC, Levey AS, Stevens LA, et al. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol. 2009;20(10):2214–2222.
   PubMed Web of Science ®Google Scholar
• Luc G, Bard JM, Lesueur C, PRIME Study Group, et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis. 2006;185(2):375–380.
   PubMed Web of Science ®Google Scholar
• Bi M, Huang Z, Li P, et al. The association between elevated cystatin C levels with myocardial infarction: a meta-analysis. Int J Clin Exp Med. 2015;8(11):20540–20547.
   PubMed Web of Science ®Google Scholar
• Bachorzewska-Gajewska H, Malyszko J, Malyszko J, et al. Obesity as a risk factor of chronic kidney disease in patients undergoing primary angioplasty. Pol Arch Med Wewn. 2006;116:916–923.
   PubMedGoogle Scholar
• Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63(2):654–661.
   PubMed Web of Science ®Google Scholar
• Park M, Yoon E, Lim YH, et al. Renal hyperfiltration as a novel marker of all-cause mortality. J Am Soc Nephrol. 2015;26(6):1426–1433.
   PubMed Web of Science ®Google Scholar
• Dupuis ME, Nadeau-Fredette AC, Madore F, et al. Association of glomerular hyperfiltration and cardiovascular risk in middle-aged healthy individuals. JAMA Netw Open. 2020;3(4):e202377.
   PubMed Web of Science ®Google Scholar
• Eriksen BO, Lochen ML, Arntzen KA, et al. Subclinical cardiovascular disease is associated with a high glomerular filtration rate in the nondiabetic general population. Kidney Int. 2014;86(1):146–153.
   PubMed Web of Science ®Google Scholar
• Rognant N, Laville M. To live with normal GFR: when higher is not better. Kidney Int. 2014;86(1):10–13.
   PubMed Web of Science ®Google Scholar
• Westerman S, Wenger NK. Women and heart disease, the underrecognized burden: sex differences, biases, and unmet clinical and research challenges. Clin Sci. 2016;130(8):551–563.
   Web of Science ®Google Scholar
• Lew J, Sanghavi M, Ayers CR, et al. Sex-based differences in cardiometabolic biomarkers. Circulation. 2017;135(6):544–555.
   PubMed Web of Science ®Google Scholar
• Mathisen UD, Melsom T, Ingebretsen OC, et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. JASN. 2011;22(5):927–937.
   Web of Science ®Google Scholar
• Melsom T, Fuskevag OM, Mathisen UD, et al. Estimated GFR is biased by non-traditional cardiovascular risk factors. Am J Nephrol. 2015;41(1):7–15.
   PubMed Web of Science ®Google Scholar
• Sundin PO, Sjostrom P, Jones I, et al. Measured glomerular filtration rate does not improve prediction of mortality by cystatin C and creatinine. Nephrol Dial Transplant. 2017;32(4):663–670.
   PubMed Web of Science ®Google Scholar